Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
JAMA Network Open | February 18, 2022 | Volume: 5 | Issue: 2 | Pages: e2149040
10.1001/jamanetworkopen.2021.49040
| PMID 35179586